Replies to post #94554 on Biotech Values

[genisi]

AMGN - health care reform impact :

"Provisions of the U.S. health-care overhaul law, including one that increases fees paid by drugmakers, cost Amgen $33 million in the first quarter and will increase costs by $200 million to $250 million this year, said George Morrow, the company’s executive vice president for global operations, in a conference call with analysts. The company won’t benefit from greater numbers of Americans being covered by health insurance until 2014, he said."

http://www.bloomberg.com/apps/news?pid=20601202&sid=ahFnRezRZRLQ

[genisi]

So far, NVS is the only Big Pharma that hasn’t lowered sales and EPS guidance to account for ObamaCare. Why hasn’t it? Simple arithmetic: 60% of NVS’ sales come from the pharma division and only one-third half of that comes from the US

The other side of the coin - NVS is much more exposed to Europe/Euro and might face headwind from the crisis there.